"Indomethacin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes.
| Descriptor ID |
D007213
|
| MeSH Number(s) |
D03.633.100.473.420
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indomethacin".
Below are MeSH descriptors whose meaning is more specific than "Indomethacin".
This graph shows the total number of publications written about "Indomethacin" by people in this website by year, and whether "Indomethacin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 7 | 8 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indomethacin" by people in Profiles.
-
Perioperative Use of Cefazolin and Indomethacin for Physical Examination-Indicated Cerclages to Improve Gestational Latency. Obstet Gynecol. 2020 06; 135(6):1409-1416.
-
Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). J Perinatol. 2019 05; 39(5):599-607.
-
Polymer Nanocoating of Amorphous Drugs for Improving Stability, Dissolution, Powder Flow, and Tabletability: The Case of Chitosan-Coated Indomethacin. Mol Pharm. 2019 03 04; 16(3):1305-1311.
-
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr. 2019 02; 205:41-48.e6.
-
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol. 2013 Mar; 108(3):410-5.
-
Epithelium-dependent modulation of responsiveness of airways from caveolin-1 knockout mice is mediated through cyclooxygenase-2 and 5-lipoxygenase. Br J Pharmacol. 2012 Oct; 167(3):548-60.
-
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12; 366(15):1414-22.
-
Polyunsaturated fatty acids block platelet-activating factor-induced phosphatidylinositol 3 kinase/Akt-mediated apoptosis in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2008 May; 294(5):G1181-90.
-
Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. J Pediatr. 2008 Aug; 153(2):183-9.
-
A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol. 2008 Mar; 5(3):172-6.